decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2000 OIG Advisory Opinions / Opinion 00-05 - OIG Approves Copay, Deductible Waivers For National Trial
Subscribe or sign in to view the full article.
Article Overview
This short advisory-opinion summary explains an Office of Inspector General review of cost-sharing waivers tied to participation in a national clinical study. It is relevant to compliance, legal, and reimbursement audiences that track federal fraud-and-abuse guidance, especially where clinical trial participation, beneficiary cost-sharing, and advisory opinions intersect.
Why This Topic Matters
Organizations involved in clinical studies and healthcare compliance may need to understand how OIG evaluated participant cost-sharing waivers in the context of a national trial. The article provides a concise example of fraud-and-abuse oversight affecting study design, participation, and financial arrangements.
What You Will Learn
- The general subject of an OIG advisory opinion involving a national clinical trial
- How the summary frames participant cost-sharing waivers in relation to compliance review
- Why federal fraud-and-abuse guidance can matter for clinical research participation arrangements
- What broad factors the OIG considered when evaluating the arrangement at a high level
Who Should Read This
- Healthcare compliance professionals
- Legal and regulatory teams
- Clinical research administrators
- Revenue cycle and reimbursement staff
- Fraud-and-abuse counsel
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com